Some of them have continued receiving crizotinib in combination with other locoregional therapies, and the reported outcomes have demonstrated that patients with advanced ALK‐positive NSCLC may derive substantial clinical benefit from continuing crizotinib beyond the RECIST‐defined PD. This evidence concerns the gene ALK and non-small cell lung carcinoma.